A U.S. cannabis company has made a bid to acquire Aurora Cannabis Inc., a company based in Edmonton. Aurora has formed a special committee to review the offer after Curaleaf Holdings Inc. announced its intention to purchase all shares of the Canadian firm. If successful, the acquisition would create a global cannabis entity with operations in 17 countries spanning Europe, North America, and other international markets.
Curaleaf, headquartered in Stamford, Conn., disclosed that its attempts to privately negotiate with Aurora’s leadership were fruitless, leading to the public proposal. Despite sending formal letters of intent on June 23 and July 7, Curaleaf claimed that Aurora’s board declined to engage in substantive discussions about the offer.
In response, Curaleaf proposed a payment of $4 US per share to Aurora shareholders, along with an additional $0.75 US in cash for each share. Aurora acknowledged receipt of the letters but disputed Curaleaf’s assertion that it had rejected the offer outright. The Canadian company stated that it was open to ongoing dialogue and had been in contact with Curaleaf’s CEO as recently as July 24.
Aurora plans to establish a special committee of independent directors to evaluate the proposal and determine its impact on stakeholders. The company emphasized that there is no guarantee of reaching a deal and assured that its operations will continue uninterrupted during the process.
While acknowledging Curaleaf’s interest, analysts at TD Cowen expressed reservations about the offer, believing that it undervalues Aurora’s long-term potential. They highlighted Aurora’s market leadership in medical cannabis, diverse product portfolio, robust financial position, and adeptness in navigating global regulatory frameworks as factors that could yield substantial value over time.
Curaleaf’s CEO emphasized that merging the two companies would leverage their combined strengths, aiming to create a more diversified global platform. The companies collectively generated over $1.5 billion US in revenue in the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US from the proposed acquisition.
The proposed merger is seen as beneficial for both Curaleaf and Aurora shareholders, offering an opportunity to capitalize on a broader international presence and favorable U.S. regulatory trends.